Monitor insider transaction filings for Poole's initial stock option and RSU grants, and assess any potential influence on corporate governance or audit oversight. No immediate trading impact expected.
Price Chart
Executive Summary
Acadia Pharmaceuticals appointed Jonathan M. Poole to its board of directors and the Audit Committee, effective March 3, 2026. Poole will receive cash retainers totaling $62,500 annually (prorated) and initial equity awards with a target fair value of $200,000, plus a prorated annual grant valued at $95,300.
Key Facts
- Jonathan M. Poole appointed to the Board of Directors and Audit Committee effective March 3, 2026
- Poole is a non-employee director serving as a Class II director with term expiring at the 2027 Annual Meeting
- He will receive annual cash retainers of $50,000 (Board) and $12,500 (Audit Committee), prorated and payable per policy
- Received initial equity grant with target fair value of $200,000, split equally between stock options and RSUs, vesting over three years
- Received prorated annual equity grant with target fair value of $95,300, split equally between options and RSUs, vesting over one year or by next annual meeting
- Starting at 2026 Annual Meeting, eligible for annual equity grants with target value of $400,000
Financial Impact
Approximately $357,800 in total initial compensation (cash and equity) for the appointment, with ongoing annual cash compensation of $62,500 and equity grants of $400,000
Risk Factors
- Potential dilution from new equity grants
- Limited immediate operational impact from board appointment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092213 |
| Document: 0001193125-26-092213-index-headers.html | 0001193125-26-092213 |
| Document: 0001193125-26-092213-index.html | 0001193125-26-092213 |
| Document: 0001193125-26-092213.txt | 0001193125-26-092213 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | 8-K | $27.52 $26.40 | ▼ −4.09% | ▼ −4.19% | $19.95 (−27.51%) |
Aug 17, 2026 6w ago | Institutional Cluster | $29.01 $29.65 | ▲ +2.21% | ▲ +3.40% | $19.95 (−31.23%) |
Aug 7, 2026 7w ago | Insider Cluster | $29.39 $29.01 | ▼ −1.29% | ▼ −1.25% | $19.95 (−32.12%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.39 $21.60 | ▼ −0.98% | ▼ −0.55% | $19.95 (+6.73%) |
May 6, 2026 21w ago | 8-K | $22.56 $22.18 | ▲ +1.68% | ▲ +3.19% | $19.95 (+11.57%) |
May 4, 2026 21w ago | Insider Cluster | $22.19 $21.80 | ▼ −1.76% | ▼ −4.69% | $19.95 (−10.09%) |
Mar 25, 2026 27w ago | Insider Cluster | $22.01 $22.32 | ▲ +1.41% | ▲ +1.65% | $19.95 (−9.36%) |
Mar 5, 2026 30w ago | 8-K | $22.40 $21.27 | ▼ −5.04% | ▼ −2.81% | $19.95 (−10.94%) |
Feb 25, 2026 31w ago | 8-K | $24.64 $22.40 | ▼ −9.09% | ▼ −7.96% | $19.95 (−19.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access